Vantage Point: Putting secondary research first

David Berman
David Berman

With pressure from payors to reduce what they pay for medicines and healthcare overall, healthcare companies are also pressed to cut costs. Simultaneously, market research departments must find innovative ways of obtaining insights to better demonstrate value while reducing costs. This means a shift to cost-effective secondary research instead of costly primary research.

As I pull out my crystal ball, I see a day where we WANT to use secondary research first. The data are rich. Access to real-world data is abundant. Because markets around the world require the use of health information technology, we have access to anonymized patient data like never before.  With privacy protections, we can follow patient-level activities from healthcare initiation, diagnosis, treatment and ultimately, outcomes.   Through de-identified biomarkers and lab work, we can view qualitative patient assessments.  Imagine…front-end tools will enable market researchers to query almost anything.

No longer can market researchers shy from secondary data.  We can make more accurate decisions about behaviors based on sample sizes in the millions!  

I also see the need for a new kind of market researcher.  One able to turn analytics into concrete ideas; one with knowledge of the industry, therapeutic areas, customers and drivers to success; and one who can put it all together and catalyze business growth.

Is this the end of primary research and primary researchers?  Absolutely not.  However, I do believe the balance will shift to a new kind of market researcher in the future.  Those starting out now should focus on what skill sets will be important in the future and less on those that define success today.

David Berman is associate vice president, global market research and analytics, Merck.

You must be a registered member of MMM to post a comment.

Email Newsletters

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.